Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

June 21, 2024

To,
The Dy. Gen Manager
Corporate Relationship Dept. **BSE Limited**PJ Tower, Dalal Street,
Mumbai- 400 001

Equity Scrip Code:531910

Dear Sir/Madam,

Sub: Outcome of Meeting of Board of Directors held on June 21, 2024.

Ref: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015

Pursuant to Regulation 30 read with other applicable Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we hereby inform you that the Board of Directors of the Company at their board meeting held today i.e. Friday, June 21, 2024 has considered and approved the following: -

1. The offer, Issuance and allotment: -

Upto 10000000 (One crore Only) fully paid-up Equity Shares of face value of Rs. 10/- (Rupees Ten Only) each and out of which 55,00,000 (Fifty Five Lakhs) equity shares to be allotted to the persons belongs to Promoter, Promoter Group category and 45,00,000 (Forty Five Lakhs) equity shares to be allotted to the persons belong to Public category on preferential basis in terms of Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (the "ICDR Regulations") as amended, Companies Act, 2013 and other applicable laws, at price of Rs. 40/- (Rupees Forty Only) per share including premium of Rs. 30/- (Rupees Thirty Only) per share in accordance with Regulation 165 of the ICDR Regulations as the shares of the Company are infrequently traded on the stock exchange, aggregating upto maximum amount of Rs. 40,00,00,000/-(Rupees Forty Crores Only).

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

The above preferential issue of equity shares is subject to the approval of shareholders of the Company at the ensuing Extra Ordinary General Meeting (EGM) and such regulatory/statutory authorities as may be applicable.

The Detailed disclosure as required under Regulation 30(6) read with Schedule III, Part A, Para A of the SEBI Listing Regulations and the SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July, 2023 for preferential issue is attached herewith as an **Annexure-A**.

- 2. We hereby inform you that the Company has decided to hold the Extra-Ordinary General Meeting of the Company on Friday, 26th July, 2024.
- 3. Approval of Notice of Extra-Ordinary General Meeting dated 21st June, 2024
- 4. The remote e-voting period will commence from Tuesday, 23rd July, 2024 at 9.00 a.m. and would end on Thursday, 25th July, 2024 at 5.00 p.m. During this period, members of the Company, holding shares either in physical form or in dematerialized form, as on Friday, 19th July, 2024 (cut-off date for remote e-voting and e-voting), may cast their vote through remote e-voting and e-voting. Those shareholders who would not vote through remote e-voting and who are otherwise not debarred from e-voting can cast their vote through e-voting during the EGM.

The Board Meeting commenced at 5.00 p.m. and concluded at 6.35 p.m.

You are requested to take the same on your record.

Thanking You, Yours Faithfully,

For Madhuveer Com 18 Network Limited

Himani Vora Company Secretary & compliance officer ACS: A73750



Reg. Office.: Office No # 812, Anand Mangal – III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363 Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

Annexure A

Disclosure with respect to the preferential issue as required under Regulation 30(6) read with Schedule III, Part A, Para A of the SEBI Listing Regulations and the SEBI Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July, 2023

S.N.	Particulars	Details				
1	Types of Securities proposed to be issued	quity Shares having face value Rs. 10/- each to the person belongs Promoter, Promoter Group and Public				
2	Types of Issuances	Issue of equity shares on preferential basis in accordance with the provisions of SEBI (ICDR) Regulations, 2018, as amended ("ICDR Regulations") and other applicable laws				
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued (Approximately)	Upto 10000000 Equity Shares (One Crore only) of the face value of Rs. 10/- each (Rupees Ten Only) fully paid up at a price of Rs. 40/- (Rupees Forty Only) per equity share including premium of Rs.30/- (Rupees Thirty Only) per share aggregating upto Rs.40,00,00,000/- (Rupees Forty Crores Only). As the equity shares of the Company are infrequently traded on stock exchange therefore the price is determined in accordance with Regulation 165 of the ICDR Regulations. The preferential issue will be undertaken for cash consideration The price of the Equity Shares to be allotted shall be subject to appropriate adjustments as permitted under applicable laws.				
4	Name of the Investors	The details of equity shares to whom allotted are Sr. Name of the proposed investor No.	Maximum Nos. of securities to be Allotted			
		 Equity Shares Dhruvin Shah (person belonging to promoter and promoter group category) Dakshesh Shah (person belonging to promoter and promoter group category) 	2700000 500000			

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

		3	Sheetal Shah (person belonging to promoter and promoter group category)				300000	
		4	Sagar Shah (person belonging to promoter and promoter group category)				1000000	
		5	Samir Shah (person belonging to promoter and promoter group category)				500000	
		6	Shweta Shah (person belonging to promoter and promoter group category)				500000	
		7	Meet Kariya (person belonging to public category)			500000	500000	
		8	Jay Kariya (person belonging to public category)			500000	500000	
		9	Shlok Rathod (person belonging to public category)			350000	3500000	
5	Post allotment of securities- outcome of	Details of the shareholding of Investors in the Company, prior to and after the proposed Preferential Issue of equity shares are as under:						
		after th	ne proposed Preferen	-			-	
	securities- outcome of the subscription		ne proposed Preference of Allottees	-	f equity		as under:	
				ntial Issue o	f equity	shares are *Post issues	as under:	
		Namo		Pre issue Sharehol No. of	ding % of share holdi	*Post iss sharehold No. of	as under: ue ding % of shareho	
		Namo Dhru	e of Allottees	Pre issue of Sharehol No. of shares	ding % of share holdi ng	*Post iss sharehold No. of Shares	as under: ue ding % of shareho lding	
		Dhrur Daksl	e of Allottees	Pre issue of Sharehold No. of shares	ding % of share holdi ng 36	*Post iss sharehold No. of Shares	as under: ue ding % of shareho lding 33.39	
		Dhrur Daksl	vin Shah	Pre issue of Sharehol No. of shares 8812486	ding % of share holdi ng 36	*Post iss sharehold No. of Shares 1151248 6	as under: ue ding % of shareho lding 33.39	

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363 Email: tohealpharmachem@gmail.com CIN: L24230G]1995PLC026244

		Shweta Shah	Nil	Nil	500000	1.45		
		Meet Kariya	1250000	5.11	1750000	5.08		
		Jay Kariya	1250000	5.11	1750000	5.08		
		Shlok Rathod	2500000	10.21	6000000	17.40		
6	Issue Price	Rs. 40/- (Rupees Forty Only) including premium of including premium of Rs. 30/- (Rupees Thirty Only) per equity share as per regulation 165 of SEBI (ICDR) Regulation, 2018.						
7	Number of Investor	9						
9	Any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not Applicable						

Thanking you, Yours faithfully,

For Madhuveer Com 18 Network Limited

Himani Vora Company Secretary & compliance officer ACS: A73750

